Compare ZIM & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZIM | ADPT |
|---|---|---|
| Founded | 1945 | 2009 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 2021 | 2019 |
| Metric | ZIM | ADPT |
|---|---|---|
| Price | $20.20 | $16.40 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $15.04 | ★ $16.70 |
| AVG Volume (30 Days) | ★ 3.3M | 1.9M |
| Earning Date | 03-11-2026 | 02-05-2026 |
| Dividend Yield | ★ 19.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.31 | N/A |
| Revenue | ★ $7,587,100,000.00 | $252,754,000.00 |
| Revenue This Year | N/A | $50.86 |
| Revenue Next Year | N/A | $0.53 |
| P/E Ratio | $2.59 | ★ N/A |
| Revenue Growth | 1.63 | ★ 42.57 |
| 52 Week Low | $11.04 | $6.26 |
| 52 Week High | $24.47 | $20.76 |
| Indicator | ZIM | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 40.69 | 40.38 |
| Support Level | $22.51 | $17.65 |
| Resistance Level | $22.61 | $19.80 |
| Average True Range (ATR) | 0.97 | 1.08 |
| MACD | -0.32 | -0.21 |
| Stochastic Oscillator | 3.64 | 0.87 |
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).